Status:
UNKNOWN
A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis
Lead Sponsor:
West China Hospital
Conditions:
Primary Biliary Cholangitis
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
This study evaluates the effect of 18-22mg/kg/d Ursodeoxycholic in refractory Primary Biliary Cholangitis
Eligibility Criteria
Inclusion
- Patients diagnosed with primary biliary cholangitis
- Treated with Ursodeoxycholic Acid in West China Hospital for at least 6 month and suboptimal response to Ursodeoxycholic Acid
Exclusion
- Autoimmune hepatitis
- Primary sclerosing cholangitis
Key Trial Info
Start Date :
January 30 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2019
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03345589
Start Date
January 30 2018
End Date
January 1 2019
Last Update
May 3 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West China Hospital
Chengdu, Sichuan, China, 610041